KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATFurniture, Fixtures and OtherGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Boston Scientific (BSX) Shares Outstanding (2016 - 2026)

Boston Scientific's Shares Outstanding history spans 18 years, with the latest figure at $1.7 billion for Q1 2026.

  • On a quarterly basis, Shares Outstanding changed 0.41% to $1.7 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $1.7 billion, a 0.41% change, with the full-year FY2025 number at $1.7 billion, changed 0.49% from a year prior.
  • Shares Outstanding hit $1.7 billion in Q1 2026 for Boston Scientific, roughly flat from $1.7 billion in the prior quarter.
  • Over the last five years, Shares Outstanding for BSX hit a ceiling of $1.7 billion in Q1 2026 and a floor of $10.1 million in Q1 2023.
  • Historically, Shares Outstanding has averaged $1.6 billion across 5 years, with a median of $1.7 billion in 2024.
  • Biggest five-year swings in Shares Outstanding: skyrocketed 16723.15% in 2022 and later grew 0.41% in 2026.
  • Tracing BSX's Shares Outstanding over 5 years: stood at $1.7 billion in 2022, then grew by 1.91% to $1.7 billion in 2023, then increased by 0.51% to $1.7 billion in 2024, then increased by 0.49% to $1.7 billion in 2025, then rose by 0.19% to $1.7 billion in 2026.
  • Business Quant data shows Shares Outstanding for BSX at $1.7 billion in Q1 2026, $1.7 billion in Q4 2025, and $1.7 billion in Q3 2025.